Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRB-913 in Obesity
NCT07310901Phase 1Completed
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CRB-913 in obesity (5 arms), sponsored by Corbus Pharmaceuticals Holdings, Inc. Primary endpoints: Maximum Plasma Concentration at 48 hours, Time to Maximum Plasma Concentration at 48 hours and 3 more. Started Dec 2025; status: completed.
02
Drugs
CRB-913
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07310901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310901.